Hypertrophic Cardiomyopathy (HCM) is a genetic heart condition characterized by the thickening of the heart muscle, particularly the left ventricle. This thickening can impede the heart's ability to efficiently pump blood. HCM is often hereditary, and individuals with a family history of the condition are at an increased risk. While some people with HCM may experience no symptoms, others may suffer from chest pain, shortness of breath, or fatigue. In severe cases, HCM can lead to abnormal heart rhythms and an increased risk of sudden cardiac arrest. Diagnosis typically involves a combination of medical history, physical examinations, and diagnostic tests such as echocardiograms. Treatment options aim to alleviate symptoms and may include medications, lifestyle modifications, or, in extreme cases, surgical procedures. Regular monitoring and follow-up with healthcare providers are crucial for managing HCM and preventing complications.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India